NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn ...

Novo Nordisk's recent decline suggests it may be a Buy again, with strong growth prospects in diabetes and obesity treatments ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Novo Nordisk shares rose after the drugmaker reported strong sales growth for its blockbuster obesity and diabetes drugs and issued a forecast for full-year 2025 results that topped analysts ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Find insight on Novo Nordisk, GSK and more in the latest Market Talks covering Health Care.

Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by ...

Novo Nordisk (NVO) reports Q4 earnings with expectations of 86 cents EPS and $11.40B revenues. Stock down 29.55% YOY, 4.81% ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill. Novo Nordisk already makes semaglutide ...